Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective

Biomed Pharmacother. 2022 Nov 9;157:113991. doi: 10.1016/j.biopha.2022.113991. Online ahead of print.ABSTRACTIcariin (ICA) is a kind of natural flavonoid compound monomer, which is derived from the extract of dried stems and leaves of Epimedium. Modern pharmacological studies have found that ICA has broad bioactive function in affecting the biological processes of a variety of cancers, including breast cancer, colorectal cancer, hepatocellular carcinoma, esophageal cancer and other cancers, which indicates that ICA has promising application value in the treatment of cancer patients in the future. Nevertheless, the targets and molecular mechanisms of ICA in cancer treatment have not been elucidated in detail. Therefore, in this review, we systematically summarizes the current research progress of ICA in a series of cancers. In particular, an emphasis is placed on the mechanism of ICA and its future development direction, aiming at providing relevant theoretical basis for the development and application of ICA in the future cancer treatment strategies.PMID:36370524 | DOI:10.1016/j.biopha.2022.113991

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 12, 2022 Category: Drugs & Pharmacology Authors: Yufang Liu Han Yang Jie Xiong Juanjuan Zhao Mengmeng Guo Jing Chen Xu Zhao Chao Chen Zhixu He Ya Zhou Lin Xu Source Type: research